Utah Medical Products (NASDAQ:UTMD) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?

Utah Medical Products, Inc. (NASDAQ:UTMD)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $61.15 and traded as high as $65.68. Utah Medical Products shares last traded at $65.42, with a volume of 6,799 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Utah Medical Products from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, February 25th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Utah Medical Products Price Performance

The stock’s 50-day moving average price is $65.56 and its 200 day moving average price is $61.15. The firm has a market cap of $209.48 million, a P/E ratio of 19.46 and a beta of 0.37.

Utah Medical Products (NASDAQ:UTMD) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $0.82 EPS for the quarter. The business had revenue of $8.72 million for the quarter. Utah Medical Products had a net margin of 28.90% and a return on equity of 9.17%.

Utah Medical Products Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 3rd. Stockholders of record on Tuesday, March 17th were given a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend was Tuesday, March 17th. Utah Medical Products’s payout ratio is currently 36.69%.

Institutional Trading of Utah Medical Products

Several institutional investors and hedge funds have recently added to or reduced their stakes in UTMD. Brandes Investment Partners LP raised its position in Utah Medical Products by 4.0% during the fourth quarter. Brandes Investment Partners LP now owns 351,322 shares of the medical instruments supplier’s stock worth $19,660,000 after acquiring an additional 13,392 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Utah Medical Products by 1.3% during the third quarter. Dimensional Fund Advisors LP now owns 200,032 shares of the medical instruments supplier’s stock worth $12,596,000 after acquiring an additional 2,566 shares in the last quarter. Geode Capital Management LLC raised its position in Utah Medical Products by 6.5% during the second quarter. Geode Capital Management LLC now owns 114,816 shares of the medical instruments supplier’s stock worth $6,537,000 after acquiring an additional 7,040 shares in the last quarter. Minerva Advisors LLC raised its position in Utah Medical Products by 0.6% during the fourth quarter. Minerva Advisors LLC now owns 93,615 shares of the medical instruments supplier’s stock worth $5,239,000 after acquiring an additional 557 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in Utah Medical Products by 4.8% during the fourth quarter. Rice Hall James & Associates LLC now owns 64,398 shares of the medical instruments supplier’s stock worth $3,604,000 after acquiring an additional 2,967 shares in the last quarter. 69.60% of the stock is owned by institutional investors.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single‐use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non‐invasive monitoring products used in acute and long‐term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end‐tidal carbon dioxide (CO₂).